Emerging immunotherapies in older adults with acute myeloid leukemia

Current Opinion in Hematology

Volumn 20, Issue 2, 2013, Pages 107-114

  Vasu, Sumithira ^a   Blum, William ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

immunotherapy; natural killer cells; older acute myeloid leukemia patients

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BORTEZOMIB; BUSULFAN; CYTARABINE; DAUNORUBICIN; DNA METHYLTRANSFERASE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADVERSE OUTCOME; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CANCER REGISTRY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CYTOLOGY; DISEASE FREE SURVIVAL; DNA METHYLATION; DRUG TARGETING; EFFECTOR CELL; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOTYPE; HLA TYPING; HUMAN; IMMUNE RESPONSE; LEUKEMOGENESIS; LOW DRUG DOSE; MEDICAL SOCIETY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; REVIEW;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; TRANSPLANTATION CONDITIONING;

EID: 84873407897     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32835d8101     Document Type: Review

References (55)

1. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007; 25:1908-1915.
2. Oran B, Weisdorf DJ. Survival for older patients with AML: a population based study. Haematologica 2012; 97:1916-1924.
3. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150:264-268.
4. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481:506-510.
5. MarcucciG, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011; 29:475-486.
6. Marcucci G, Metzeler KH, Schwind S, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 2012; 30:742-750.
7. Metzeler KH, Walker A, Geyer S, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia 2012; 26:1106-1107.
8. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28:2348-2355.
9. Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene-and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28:596-604.
10. Greiner J, Ono Y, Hofmann S, et al. Mutated regions of nucleophosmin 1 elicit both CD4(\+) and CD8(\+) T-cell responses in patients with acute myeloid leukemia. Blood 2012; 120:1282-1289.
11. Schwind S, Marcucci G, Kohlschmidt J, et al. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood 2011; 118:4188-4198.
12. Metzeler KH, Becker H, Maharry K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 2011; 118:6920-6929.
13. Becker H, Marcucci G, Maharry K, et al. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 116:788-792.
14. Maslak PG, Dao T, Krug LM, et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010; 116:171-179.
15. Ochsenreither S, Fusi A, Busse A, et al. Wilms Tumor Protein 1 (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow. J Immunother 2011; 34:85-91.
16. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349:2042-2054.
17. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28:562-569.
18. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010; 107:7473-7478.
19. Blum W, Schwind S, Tarighat SS, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood 2012; 119:6025-6031.
20. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30:2670-2677.
21. Blum W, Schwind S, Tarighat SS, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood 2012; 119:6025-6031.
22. Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012; 119:6198-6208.
23. Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012; 30:3924-3931.
24. Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012; 379:1508-1516.
25. Burnett AK, Hills RK, Hunter AE, et al. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia 2013; 27:75-81.
26. Koreth J, Aldridge J, Kim HT, et al. Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant 2010; 16:792-800.
27. Chevallier P, Szydlo RM, Blaise D, et al. Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC. Biol Blood Marrow Transplant 2012; 18:289-294.
28. SorrorML, Sandmaier BM, Storer BE, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011; 306:1874-1883.
29. Farag SS, Maharry K, Zhang MJ, et al. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 2011; 17:1796-1803.
30. Devine S. A phase II study of allogeneic transplantation for older patients with AML in first complete remission using a reduced intensity conditioning regimen: results from CALGB 100103/BMT CTN 0502 [abstract]. Blood 2012; 120:abstr. 230.
31. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097-2100.
32. Ruggeri L, Capanni M, Mancusi A, et al. Natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Int J Hematol 2005; 81:13-17.
33. Olson JA, Leveson-Gower DB, Gill S, et al. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood 2010; 115:4293-4301.
34. Noval Rivas M, Hazzan M, Weatherly K, et al. NK cell regulation of CD4 T cell-mediated graft-versus-host disease. J Immunol 2010; 184:6790-6798.
35. Uhrberg M, Valiante NM, Shum BP, et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997; 7:753-763.
36. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005; 5:201-214.
37. Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009; 113:726-732.
38. Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010; 116:2411-2419.
39. Sivori S, Carlomagno S, Falco M, et al. Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood 2011; 117:4284-4292.
40. Venstrom JM, Pittari G, Gooley TA, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 2012; 367:805-816.
41. Pende D, Marcenaro S, Falco M, et al. Antileukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009; 113:3119-3129.
42. Moretta A, Locatelli F, Moretta L. Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias. Immunol Rev 2008; 224:58-69.
43. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-2454.
44. Vey N, Bourhis JH, Boissel N, et al. A phase I trial of the antiinhibitory KIR monoclonal antibody IPH2101 for acute myeloid leukemia (AML) in complete remission. Blood 2012; 120:4317-4323.
45. Vey N. A phase I study of the anti-natural killer inhibitory receptor (KIR) monoclonal antibody (1-7F9, IPH2101) in elderly patients with acute myeloid leukemia (AML): clinical and immunological effects of a single dose followed by repeated dosing. Blood 2009; 114:632.
46. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051-3057.
47. Curti A, Ruggeri L, D'Addio A, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high-risk acute myeloid leukemia patients. Blood 2011; 365:725-733.
48. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-733.
49. Mardiros A. CD123-specific chimeric antigen receptor redirected T cells exhibit potent cytolytic activity and multiple effector functions against acute myeloid leukemia without altering normal hematopoietic colony formation in vitro [abstract]. Blood 2012; 120:abstr 950.
50. Tettamanti S. Targeting of acute myeloid leukemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor [abstract]. Blood 2012; 120:abstr. 3010.
51. Chu Y. Expanded natural killer (NK) cells transfected with anti-CD20 chimeric antigen receptor (CAR) mRNA have significant cytotoxicity against poor risk B-cell (CD20\+) leukemia/lymphoma (B-L/L) [abstract]. Blood 2012; 120:abstr. 3007.
52. Carpenter B. Targeting therapeutic T cells to tumour niches [abstract]. Blood 2012; 120:abstr. 3009.
53. Dahmani A. The immune 'Combination Therapy' of leukemia using adoptive transfer and TGF-b blockade [abstract]. Blood 2012; 120:abstr. 3017.
54. Stickel J. HLA ligandome analysis of acute myeloid leukemia (AML) revealed novel tumor-associated antigens for immunotherapy [abstract]. Blood 2012; 120:abstr. 3012.
55. Casucci M. Co-expression of a suicide gene in CAR-redirected T cells enables the safe targeting of CD44v6 for leukemia and myeloma eradication [abstract]. Blood 2012; 120:abstr. 949.